Investigational drug · Phase 2
Renadirsen
Also called: DS-5141b
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Duchenne Muscular Dystrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Renadirsen"
First trial start
2020
Jun 30, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Renadirsen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Duchenne Muscular Dystrophy
Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Renadirsen" as an intervention, largest first.
- Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular DystrophyActive, not recruiting
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
NCT04433234 · 8 participants (planned) · Start Jun 30, 2020 · Primary completion Jan 31, 2027
Drug: DS-5141b · For: Duchenne Muscular Dystrophy
Sites: Tokyo, Japan; Hyōgo, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Tissue distribution of renadirsen sodium, a dystrophin exon-skipping antisense oligonucleotide, in heart and diaphragm after subcutaneous administration to cynomolgus monkeys.
Yamamura N, Takakusa H, Asano D, et al. · Nucleosides Nucleotides Nucleic Acids 2025
- Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy.
Wilton-Clark H, Yokota T · Pharmaceutics 2023
- Renadirsen, a Novel 2'OMeRNA/ENA® Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo.
Ito K, Takakusa H, Kakuta M, et al. · Curr Issues Mol Biol 2021
Also in development for Duchenne Muscular Dystrophy
- AOC 1044Phase 33 trials
Avidity Biosciences, Inc. · DMD, Duchenne Muscular Dystrophy, Exon 44
- DeramiocelCAP-1002, Allogeneic Cardiosphere-Derived CellsPhase 32 trials
Capricor Inc. · Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic
- SGT-003Phase 32 trials
Solid Biosciences Inc. · Duchenne Muscular Dystrophy, Advanced Solid Tumor
- SevasemtenPhase 24 trials
Edgewise Therapeutics, Inc. · Becker Muscular Dystrophy, Duchenne Muscular Dystrophy
- BrogidirsenNS-089, NCNP-02Phase 23 trials
NS Pharma, Inc. · Duchenne Muscular Dystrophy, Exon 44, DMD
- BMN 351Phase 22 trials
BioMarin · Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy
- SAT-3247Phase 22 trials
Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD
- WVE-N531Phase 22 trials
Wave Life Sciences USA, Inc. · Duchenne Muscular Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Daiichi Sankyo.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.